The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab improved progression-free survival over fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab in treatment-naïve chronic lymphocytic leukemia (TN CLL), according
Results from the phase 3 ASC4FIRST study presented at the 2024 American Society of Hematology Annual Meeting & Exposition showed that asciminib had
Addition of tafasitamab, a humanized CD19-targeting monoclonal antibody (mAb), to lenalidomide plus rituximab resulted in significant and clinically meaningful improvement in progression-free survival (PFS),
Results from a prospective study presented at the American Society of Hematology Annual Meeting & Exposition showed that tobacco smoking was associated with
The Society of Hematologic Oncology (SOHO) has announced that its 2025 meeting will be held between Wednesday, September 3, 2025, and Saturday, September
The chimeric antigen receptor (CAR)-T cell therapy CTX130 (volamcabtagene durzigedleucel) showed encouraging results in patients with heavily pretreated relapsed or refractory T-cell lymphoma,
FS118, a new potential immune checkpoint blocker, was well tolerated in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) with
Maintenance therapy discontinuation in patients with deep measurable residual disease (MRD) negativity (<10⁻⁶ or <10⁻⁷) is associated with low rates of disease resurgence
Rami Komrokji, MD, of the Moffitt Cancer Center in Tampa, Florida, and 2024-2025 SOHO President Phillip Scheinberg, MD, PhD, of the Hospital Sao
CtDNA is a valuable biomarker for monitoring disease burden and predicting durable clinical benefit in second-line large B-cell lymphoma (LBCL) treatment, according to
